AllSci News
Partner Therapeutics seeking third indication for Bizengri in NRG1 fusion-positive cholangiocarcinoma
Partner Therapeutics submitted a supplemental Biologics License Application (sBLA) to the US FDA on April 14, 2026 for Bizengri (zenocutuzumab-zbco),...
Bold Therapeutics' Bold-100 shows lower neuropathy rates in Phase I/II FOLFOX combination trial
Bold Therapeutics reported that BOLD-100, its ruthenium-based anticancer agent, was associated with substantially lower rates of oxaliplatin-induced...
AIM ImmunoTech's rintatolimod advances to Phase III trial for pancreatic cancer on positive signals
AIM ImmunoTech (NYSE American: AIM) announced plans to advance rintatolimod (Ampligen) into a Phase III trial for late-stage pancreatic ductal...
University Hospital Erlangen achieves CD19 CAR-T remission in autoimmune hemolytic anemia with ITP
University Hospital Erlangen researchers report CD19 CAR-T-induced remission in refractory autoimmune hemolytic anemia with ITP and antiphospholipid...
Immutep secures FDA Orphan Drug Designation for eftilagimod alfa in soft tissue sarcoma
Immutep (ASX: IMM; NASDAQ: IMMP) announced receipt of FDA orphan drug designation for eftilagimod alfa in soft tissue sarcoma (STS), a rare…
Aligos hands pevifoscorvir license to Xiamen Amoytop in USD 445m deal
Aligos Therapeutics (Nasdaq: ALGS) has entered an exclusive license agreement with Xiamen Amoytop Biotech Co., Ltd. covering pevifoscorvir sodium, an oral...
RemeGene receives USD 650m upfront fee from AbbVie
RemeGen Co. (HKEX: 9995) confirmed on April 15 that it has received the USD 650 million upfront payment from AbbVie (NYSE: ABBV) under the exclusive license...
PrecisionLife and Ovation collaborate on AI-driven GLP-1 stratification test
PrecisionLife and Ovation have entered a collaboration agreement to commercialize a GLP-1 stratification test platform combining AI-driven genomic analytics...
Pfizer-backed Storm Therapeutics closes USD 56m Series C for RNA drug in sarcoma
STORM Therapeutics, a Cambridge, UK-based clinical-stage biotechnology company focused on targeting RNA modifications to treat cancer, has closed a USD 56...
Boehringer Ingelheim, Zai Lab to try out dual DLL3-targeting combo for SCLC, NECs
Boehringer Ingelheim and China-based Zai Lab (NASDAQ: ZLAB; HKEX: 9688; Shanghai/Cambridge, Mass.) announced a clinical collaboration to evaluate a dual DLL3-targeting cancer…
Sedogen LLC secures US patent for diazoxide formulations treating Prader-Willi syndrome
Sedogen LLC (USA), a parent-led biopharmaceutical company focused on Prader-Willi syndrome, announced the issuance of US Patent 12,589,098 by the US Patent…
Dogwood/Serpin's LRP1 agonist gets FDA IND nod for chemotherapy-induced neuropathy
Dogwood Therapeutics (Nasdaq: DWTX) announced on April 15, 2026 that the US FDA has accepted an investigational new drug application for SP16, an...
New research reveals tau seed propagation patterns in Alzheimer's
Researchers at the University of Alabama at Birmingham, working with collaborators at Rush University Medical Center in Chicago and SUNY Upstate Medical...
Beeline Medicines debuts with USD 300m Series A and BMS autoimmune therapies
Beeline Medicines Corporation, a clinical-stage biotechnology company headquartered in Stamford, Connecticut, has publicly debuted with a USD 300 million...
Terremoto closes USD 108 million Series C financing for AKT1 inhibitors
Terremoto Biosciences, a clinical-stage biotechnology company based in South San Francisco, has closed a USD 108 million Series C financing round to advance...
The AllSci Brief
Free, systematic R&D and deal news. Daily.